More on Tetraphase Pharmaceuticals earnings

Tetraphase Pharmaceuticals (TTPH) posts its first earnings release after its IPO debut in April, coming in mixed for the quarter.

Q2 revenue beat, but results came in shy of estimates on a per share basis.

Revenues for the period consisted of contract and grant revenue under three U.S. government awards for the development of compounds as potential counter measures for treating bacterial bio-threat pathogens through subcontracts and a sub-award from its collaborator, CUBRC Incorporated.

R&D expenses grew, largely due to an increase in expenses related to activities under our subcontracts with CUBRC, as well as an increase in clinical costs associated with the Phase 3 program and the Phase 1 oral PK program for eravacycline.

Shares -1% AH.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs